ORA:EURONEXT PARISOrange SA Analysis
Data as of 2026-06-25 - not real-time
$124.18
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Ormat Technologies has posted a spectacular 75.8% revenue surge and its stock has rallied more than 16% since the latest earnings release, underscoring strong top‑line momentum. Operating margins above 20% and a solid profit margin of 11% demonstrate operational efficiency, yet the company’s free cash flow remains negative and debt‑to‑equity exceeds 125%, flagging balance‑sheet strain. The current price of $124.18 sits above the 200‑day SMA but below the 20‑day and 50‑day SMAs, while a RSI of 39.5 hints at near‑oversold conditions and the bearish MACD suggests short‑term downside pressure. Support around $123 offers a technical floor, with resistance near $146.4 providing upside potential if the bullish trend persists. Valuation metrics are stretched: a PE of ~60 versus an industry average of ~21 and a DCF fair value of $88.5 place the stock in the overvalued zone, though analyst targets imply a modest 7‑8% upside. The dividend yield of 0.39% and a payout ratio under 25% make the payout sustainable, but the high leverage and 30‑day volatility of over 40% amplify risk. Recent news of accelerated Enhanced Geothermal System deployments and the launch of the Ormega100 unit adds a growth catalyst, aligning with the company’s renewable‑energy focus. Overall, the stock balances strong growth narratives against elevated valuation and financial risk, suggesting a cautious but optimistic stance.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near technical support at $123
- Bearish MACD histogram indicating short‑term pressure
- High 30‑day volatility
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Robust 75.8% revenue growth and expanding geothermal portfolio
- Analyst consensus buy with median target $132.5
- Sustainable dividend and low payout ratio
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Renewable‑energy tailwinds and EGS deployment acceleration
- Diversified geographic footprint reducing single‑country exposure
- Long‑term upside potential despite current overvaluation
Key Metrics & Analysis
Financial Health
Revenue Growth75.80%
Profit Margin10.96%
P/E Ratio60.0
ROE4.91%
ROA2.03%
Debt/Equity125.51
P/B Ratio3.0
Op. Cash Flow$325.7M
Free Cash Flow$-178817120
Industry P/E21.0
Technical Analysis
TrendBullish
RSI39.5
Support$123.00
Resistance$146.39
MA 20$135.63
MA 50$126.48
MA 200$114.42
MACDBearish
VolumeStable
Fear & Greed Index88.16
Valuation
Fair Value$88.51
Target Price$133.75
Upside/Downside7.71%
GradeOvervalued
TypeBlend
Dividend Yield0.39%
Risk Assessment
Beta0.88
Volatility41.61%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.